AbCellera Biologics Inc.
ABCL
12.38 $
1 day: +1.31% (+0.16 $)
The alert is saved directly without jumping back to the homepage.
Price alerts for ABCL
Please log in to view and save price alerts.
Finanzen
Company info
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Aktuelle News
-
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?
Vorschau anzeigen
On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will fund all research and development and retain commercialization rights. In return, […]
-
AbCellera (ABCL) Q2 2026 Earnings Call Transcript
Vorschau anzeigen
Lead program ABCL635 Phase 2 enrollment complete with data expected in August.
-
AbCellera Biologics (ABCL) Is Up 60.3% After Strong Phase 2 Menopause Data For ABCL635 - Has The Bull Case Changed?
Vorschau anzeigen
AbCellera Biologics recently reported that its investigational antibody ABCL635 achieved statistically significant Phase 2 results, with a single 600 mg subcutaneous dose reducing both the frequency and severity of moderate-to-severe menopausal hot flashes versus placebo while showing a favorable tolerability profile over four weeks. By pairing these data with improvements in sleep and patient-reported outcomes, ABCL635 positions AbCellera as an emerging player in the large, under-served...
-
AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal
Vorschau anzeigen
The latest analyst update on AbCellera Biologics reflects a higher Fair Value estimate of US$14.63 compared with the prior figure of US$10.43. This shift aligns with more constructive Street research that follows recent clinical data and new partnership agreements. These developments have prompted several firms to revisit their rating and price target work on the stock. Read on to see how these changing assumptions fit into the broader narrative and how you can track the story from...
-
AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 Results
Vorschau anzeigen
Why ABCL635’s Phase 2 data matters for AbCellera Biologics stock AbCellera Biologics (ABCL) has become a focus for many biotech investors after announcing that ABCL635 met primary endpoints in a Phase 2 trial for menopause related hot flashes. The single dose of ABCL635 produced statistically significant reductions in both the frequency and severity of vasomotor symptoms versus placebo and was reported as well tolerated, with additional benefits in sleep and patients’ overall perception of...